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The credibility and hence value of pre-clinical and clinical cystic fibrosis gene therapy studies depend on the assays used to evaluate gene
transfer. Awareness of assay suitability, sensitivity and variability is therefore crucial to the design of experimental programmes. Here, we
review the assays that are in use to assess the efficacy of gene transfer in pre-clinical and clinical CF gene therapy research, highlight their
weaknesses and suggest possible new strategies that may help to overcome current limitations.
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Cystic fibrosis (CF) is the most common lethal mono-
genic autosomal recessive disease in the Caucasion pop-
ulation and affects approximately 70,000 individuals world-
wide. Although several organs are affected, severe lung
disease is the cause of most morbidity and mortality in CF
individuals [1]. Overall the CFTR protein is not expressed
abundantly in the lungs, but high expression is seen in
serous cells in the submucosal glands and isolated epithelial
cells in the airways [2]. It is currently unclear which of these
cell types should be the main targets for CF gene therapy,
but considering that CF (at least in the early stages) presents
as a small airway disease, we are working on the basis that
airway epithelial cells (AECs) are highly relevant targets for
CF gene therapy.
The gene underlying CF, the cystic fibrosis transmem-
brane conductance regulator (CFTR), was cloned in 1989
and encodes a chloride channel, which is located in the
apical membrane of epithelial cells [3]. Two competing
theories attempt to explain the relationship between
defective ion transport and CF lung disease. The ‘‘high
salt’’ hypothesis postulates that airway surface liquid (ASL)
in CF patients has a higher salt concentration than in non-CF
individuals, due to the inability of airway epithelial cells to
absorb chloride ions. This in turn may lead to impaired
mucociliary clearance and reduced activity of anti-microbial
peptides [4]. The ‘‘low volume’’ hypothesis (in our view, the
one better supported by the available data) postulates that
due to absent chloride transport and increased sodium
absorption the height of the ASL is reduced, leading to
impaired mucociliary clearance [5]. Reduced mucociliary
clearance, which is explained by both theories, leads to
formation of thickened dehydrated mucus, which provides
an ideal environment for bacterial infection, leading to
chronic inflammation and ultimately organ failure in the CF
lung. Whether inflammatory pathways are dysregulated in
CF airways independent of infection, or whether the
inflammatory response following bacterial infection is
exaggerated and disproportional, has been widely debated,
but a conclusive consensus has not been reached.
Proof-of-principle for CFTR gene transfer was quickly
established in vitro [6] and in an animal model [7]. The first
clinical trials in CF patients were carried out in 1993 and to
date about 30 trial protocols, most of which have been
completed, are published (see www.wiley.co.uk). Although
early hopes that CF gene therapy in the lung would be
straightforward due to the topical accessibility of the lung
were not confirmed, steady progress has been made over theyears. Here, we review the assays that are in use to assess
successful gene transfer in pre-clinical and clinical CF gene
therapy research, but also highlight their weaknesses and
suggest possible new strategies that may help to overcome
limitations of the current assays.
The UK Cystic Fibrosis Gene Therapy Consortium
(UKCFGTC) has been set up with the help of the UK
Cystic Fibrosis Trust to combine the research efforts of three
CF gene therapy groups in Edinburgh, London and Oxford,
with the expressed aim of developing effective formulations
for clinical use. This ambitious initiative has motivated us to
channel substantial resources into developing and testing
pre-clinical and clinical assays for CF gene therapy. Where
relevant, the consortium’s developments in these areas will
be described below.2. Pre-clinical endpoints of airway gene transfer
2.1. Gene transfer in wild-type animals
2.1.1. Reporter genes in lung or nasal turbinate homogenate
In the early years of gene therapy research, many viral
and non-viral gene transfer agents (GTAs) were assessed in
cell culture. However, it became quickly apparent that cell
culture results do not predict the performance of GTAs in
the lung. This is probably due to differences in proliferation
status (most cells in the lung are terminally differentiated
and do not divide), privileged access to the basolateral
membrane in cell culture but not in vivo, and possibly a
different distribution or number of receptors. As a conse-
quence of this divergence, it has become essential to
evaluate most GTAs for CF gene therapy in the airways
of animal models.
The distribution of GTAs in animal models associated
with specific administration techniques has to be carefully
examined. The mouse is the most frequently used model and
GTAs are often administered through bolus injections either
into the nose [8], or directly into the trachea [9,10]. This
type of administration may not be the most desirable for
efficient airway gene transfer, because the GTA will have
only a short contact time with the surface of airway
epithelial cells and will mainly accumulate in the alveolar
region (the so-called ‘‘pooling effect’’). Although several
groups have attempted to nebulise GTAs into the mouse
lung [11,12], this has generally been inefficient.
The nasal epithelium of mice expresses CFTR [13],
shows the characteristic bioelectric properties of humans
and is therefore an appropriate surrogate organ. Slow
Fig. 1. Efficient transfection of mouse nasal epithelium with recombinant
Sendai virus expressing h-galactosidase. Close to 100% of airway epithelial
cells express h-galactosidase, here visible as blue precipitate.
Table 1
Reporter genes commonly used to assess airway gene transfer
Abbreviated
name
Full name Mainly used for
GFP Green fluorescent
protein
Fluorescence microscopy
hgal h-galactosidase Histological staining
Chemiluminescence assay
Immunohistochemistry
CAT Chloramphenicol
acetyl transferase
ELISA
Lux Firefly luciferase Chemiluminescence assay
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catheter ensures prolonged contact time with the epithelial
surface [14] and allows characterisation of GTAs without
the added complication of limited contact time. In addition,
larger animal models such as primates [15,16], pigs [17] and
most recently sheep [18] have been used for airway gene
transfer and potentially allow testing of gene transfer using
clinically relevant delivery methods such as nebulisation.
An important advantage of the sheep and other large animal
models are that they allow repeat delivery experiments on
the same scales of material and time that are appropriate for
clinical use [19], with clinically used delivery systems.
Reporter genes encoding chloramphenicol acetyl trans-
ferase (CAT), firefly luciferase (Lux) or h-galactosidase (h-
gal) (Table 1) have been widely used for the identification
and characterisation of effective viral and non-viral GTAs
[10,14,20]. Typically, reporter gene activity is measured in
tissue homogenates using commercially available non-
radioactive chemiluminescent assays or ELISAs. In our
experience, Lux is the fastest, cheapest and most sensitive
assay (UKCFGT unpublished data). A major disadvantage
of reporter gene assays carried out on tissue homogenates is
that they do not reveal which cells have been transfected,
nor how many or where they are. For example, a candidate
GTA for CF gene therapy may be more highly efficacious in
non-epithelial cells (which are not a target for CF gene
therapy) and would give misleading results in any homo-
genate-based reporter gene assay.
2.1.2. Histological analysis of reporter gene expression
Histological analysis of reporter gene expression using
immunohistochemistry [17], green fluorescent protein
(GFP) visualisation [21] or direct staining techniques [such
as the use of 5-bromo-4-chloro-3-indolyl-beta-d-galactopyr-
anoside (X-gal)], which stains cells that express h-gal blue
[22]) are more labour intensive, but also more informative
than reporter gene assays on homogenates, as these may
reveal which cells have been transfected. However, most of
these techniques are not very sensitive and require fairly
high expression of the reporter gene in each cell [23]. (Thus,
for example, X-gal staining has been shown to under-
estimate transfection efficiency when compared to immu-
nohistochemical lacZ detection [24].) They have therefore
generally been limited in practical terms to the analysis ofmore efficient viral gene transfer agents such as Sendai virus
(SeV) [14] (Fig. 1).
More recently several groups, including our own, are
attempting to answer the ‘‘which cells where?’’ question
after non-viral gene transfer. This requires careful optimi-
sation of the signal to noise ratio due to poorer transfection
efficiencies. Cunningham et al detected h-gal expression in
46% of porcine airway epithelial cells with anti-h-gal
antibodies after transfection with the non-viral vector LID
[17]. However, it has proven difficult to reproduce these
results with other non-viral vectors. Our group is currently
evaluating more sensitive immunohistochemistry-based
techniques such as tyramide signal amplification (TSA)
[25] or rolling circle amplification (RCA) [26] for the
detection of recombinant protein (reporter gene or CFTR)
after gene transfer. However, all these techniques share the
concern that protein expression required to see a positive
signal may be much higher than the endogenous CFTR
levels we are trying to reproduce in order to correct the
defect. Ideally, screening procedures should avoid discard-
ing GTAs that fail to give a positive reporter gene signal but
are capable of delivering a therapeutic fraction (suggested to
be 5% [27,28]) of the comparatively low CFTR expression
levels seen in normal individuals. There is evidence that
under certain circumstances overexpression of CFTR is
deleterious [29,30]; also CFTR expression in vivo is
markedly heterogeneous [31]. It is possible therefore that
an efficient GTA would deliver too much CFTR, with
unknown consequences. For this reason it is essential to
further test any GTAs with CFTR as transgene, and ensure
that normal CFTR function with no undesirable side-effects
is observed (see below). If overexpression in vivo of CFTR
proves to be a problem, we can address it in several ways.
One is to use a weaker promoter to reduce transcription or to
use the endogenous CFTR promoter, which would ensure
appropriate expression in the right cell-type. However,
although much interesting development has occurred [32–
34], a functionally verified tissue-specific CFTR promoter
suitable for gene therapy is currently not available. The
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reduce translation. Given these possible interventions,
current efforts are aimed at maximising CFTR expression
to compensate for the low efficiencies of (in particular) non-
viral GTAs.
2.2. Assessment of CFTR expression and function in vitro or
ex vivo
In addition to optimising gene transfer, the capacity of
GTAs to make functional CFTR has to be determined. Non-
viral GTAs usually contain eukaryotic expression plasmids
carrying CFTR cDNA. If the same batch of plasmid is used
in different formulations, it is generally only necessary to
test each new batch of plasmid once. For this purpose the
plasmid should be combined with a lipid or polymer
formulation that is known to transfect the chosen in vitro
or ex vivo model efficiently. In contrast, every different type
of virus and even different batches of the same virus should
be assessed for their capacity to make functional CFTR.
This is necessary because viruses may silence the CFTR
transgene during viral amplification by acquiring mutations.
This may be a particular problem if the presence of wild-
type CFTR sequence disadvantages viral growth.
Several in vitro/ex vivo CFTR functional assays have
been developed and their strengths and weaknesses will be
briefly discussed.
(a) Agonist-mediated halide efflux: this assay, first
introduced by Venglarik [35] is based on the
cAMP-mediated efflux of halide through the CFTR
channel from the cell interior into the extracellular
medium. Medium is collected at frequent intervals
from adherent cells preloaded with radioactive
halide. Cyclic-AMP mediated chloride channels are
more permeable to iodide then many other chloride
transport processes [36], so 125Iodide (half life=59.6
days) is conveniently used instead of the natural
chloride radiotracer chlorine-36 (half life=300,000
years). An alternative to radiotracer based halide
efflux measurement of CFTR channel activity is the
assessment of effluxed iodide/chloride using an ion-
selective electrode (ISE). This is essentially an
electrochemical sensor based on a thin film halide-
selective membrane recognition element. Basically,
the ISE produces a potential that is proportional to
the concentration of the halide. The electrodes are
relatively inexpensive and simple to use and have
been shown to give equivalent results to the
radiotracer Fsample-replace_ assay described above
[37].
(b) Cyclic-AMP-dependent halide CFTR channel activity
assay using quinolinium salt-based halide-sensitive
fluorescent probes (6-methoxy-N-(-sulphopropyl)qui-
nolinium (SPQ) and N-(ethoxycarbonylmethyl)-6-
methoxyquinolinium bromide (MQAE)). The assay,developed by Verkman and colleagues, follows the
secretion of halide from epithelial cells by measuring
dequenching of intracellular SPQ/MQAE fluores-
cence by the effluxing halide in response to cAMP-
stimulation [38]. Many studies have used the fluo-
rescence indicators to assess chloride channel efflux.
In these studies, iodide is used as a convenient
chloride analogue because SPQ/MQAE fluorescence
is more effectively quenched by iodide than by
chloride (halide ion selectivity: iodide>bromide>ch-
loride) thus improving the signal to noise ratio in
SPQ/MQAE spectrofluorimetry. Both SPQ and
MQAE spectrofluorimetry has been used in numerous
studies to assess halide efflux in adherent cultured cell
lines and primary epithelial cells [9,39]. However,
these fluorometric assays are more expensive and
technically more difficult than the radioactive efflux
assays. In addition, fluorophore loading is fairly
invasive and the post loading recovery window needs
to be optimised, to avoid passive leaking of fluoro-
phores out of the cells. However, this time window is
often not compatible with post-transfection protocols.
(c) Ussing chamber: this allows assessment of the ion
transport properties of epithelial cell layers, either as
native tissue samples or grown in vitro on permeable
filters [40]. The change in short circuit current (DIsc)
in response to IBMX (a phosphodiesterase inhibitor)
and/or forskolin (a cAMP agonist) is the most used
measurement (e.g. see [41]). DIsc is significantly
lower in CFTR-deficient cells, so the efficacy of gene
therapy intervention can be measured by an increase
of DIsc towards normal levels. Importantly, it is
comparatively easy to discriminate the response of
CFTR from other CFTR-regulated channels, by using
specific inhibitors such as DIDS (4,4V-diisothiocyana-
tostilbene-2,2V-disulfonic acid) and glibenclamide,
which inhibit the outwardly rectifying chloride chan-
nel (ORCC) and CFTR, respectively.
(d) Patch clamping: this is a demanding technique
requiring the use of a microscope and a solute-
containing glass pipette (which acts as an electrode) to
isolate a cell or patch of membrane containing one or
more ion channels. By this means, current across
membranes of a single cell can be measured. Because
single channels can be isolated, the properties of the
channel can be examined in exquisite detail. Whole-
cell patch clamp methods have been used to inves-
tigate CFTR gene transfer [42], but the time involved
and difficulty of applying the method limit its
usefulness in this domain. However it should certainly
be considered as an endpoint in cases where indis-
putable evidence of functional CFTR at the apical
membrane is required.
Overall, results obtained from radioactive and non-
radioactive efflux assays and Ussing chambers described
U. Griesenbach, A.C. Boyd / Journal of Cystic Fibrosis 4 (2005) 89–100 93above represent average CFTR function in the entire sample
population, whereas patch-clamping and SPQ/MQAE anal-
ysis assess CFTR function in individual cells.
For the purpose of vector testing we recommend the use
of iodide efflux assays, as these are not technically difficult
and can be done with relatively high throughput using
transformed cell lines. However, one has to be certain that
the cells to be transfected do not have any endogenous
cAMP-dependent chloride channel activity. 293T cells
(ATCC) are suitable for analysis of CFTR containing
eukaryotic expression plasmids, as these cells do not have
any endogenous cAMP-dependent chloride channel activity
and transfect well (>90% of cells transfected) with Lipo-
fectamine 2000 (Gibco Life technologies). When choosing a
cell line for virus-mediated CFTR testing, one has to ensure
that the virus transfects the cell line efficiently and this will
likely vary depending on the virus to be tested. In our
experience 293T cells (for example) are suitable for analysis
of adenovirus and Sendai virus-mediated CFTR expression
(Felix Munkonge, personal communication).
2.3. CFTR gene transfer and endpoint assays in the CF
mouse
In our opinion, reporter gene expression in wild-type
mice is of limited value, for the reasons highlighted above.
Gene transfer experiments should use CFTR and relevant
CFTR-based endpoint measurements wherever possible.
Currently the CF knockout mouse is the only animal model
for CF and, although these mice do not develop the
characteristic CF lung disease, they have the same ion
transport defect as CF patients in their nasal epithelium [43].
This, combined with the fact that the nasal epithelium can be
exposed to GTAs in a time-controlled fashion (as described
above), makes the CF mouse nose a useful model organ for
assessing and optimising CFTR gene transfer.
Initially, it has been difficult and expensive to produce
sufficient CF mice for large scale gene transfer screening
programmes, because the mice were bred as heterozygotes,
with only one in four pups being a homozygote CF
knockout animal. In addition, most CF mice suffered from
severe intestinal disease, required a special fibre-free diet
and had a high post-weaning mortality rate. However, the
gut disease in CF mice has been corrected through
incorporation of a CFTR transgene under the control of
the fatty acid binding protein promoter [44]. This promoter
is thought to restrict CFTR expression to the gut and results
in CF mice that are fertile, do not have gut disease and have
normal post-weaning survival, but theoretically still have
the ion transport defect in the nasal epithelium. These mice
can be bred at similar cost to wild-type inbred animals and
therefore make a large scale screening program in CF mice
much more feasible. We are currently analysing the
electrical properties of the nasal epithelium in these mice.
Two groups have recently shown that pre-treatment of
CF mice with adenovirus-expressing CFTR amelioratesthese exaggerated responses to P. aeruginosa and B.
cepacia [45,46]. However, it is currently unclear how
CFTR expression improves host response against bacteria,
and beneficial pro-inflammatory responses to the adenoviral
backbone cannot be completely ruled out.
2.3.1. Quantification of recombinant CFTR mRNA
Recombinant CFTR mRNA has traditionally been meas-
ured after gene transfer. This is either done as a semi-
quantitative reverse transcription-polymerase chain reaction
(RT-PCR) or more recently through quantitative real-time
RT-PCR. Rose et al. have demonstrated that real-time
TaqMan RT-PCR discriminates effectively between vector-
specific and endogenous CFTR expression in the airways and
quantifies both types of mRNA accurately [47]. However,
RT-PCR assays (like the reporter gene assays described
above) have so far been carried out on mRNA extracted from
total tissue homogenates, and therefore suffer from the same
limitations, i.e. that the identity of cells and the number of
cells expressing the transgene cannot be determined. Laser
capture microdissection (LCM) of murine bronchial epithe-
lial cells coupled to real-time RT-PCR has previously been
described as a way of measuring endogenous gene expression
[48] and might be applicable to gene therapy as well. If
successful, this would allow us to determine whether
recombinant CFTR is made in airway epithelial cells and
how the amount relates to endogenous CFTR expression.
The perceived difficulty of detecting CFTR protein has
led to the use of in situ hybridisation as a means of measuring
transgene expression. This technique has the theoretical
advantage that probes can be made species or vector specific.
The low abundance of CFTR message [49] means that in
practice the method is difficult to perform; great care must be
taken in order to separate any signal from background levels.
Judicious design and preparation of a suitable probe is
essential. Nevertheless, in situ hybridisation has been used
successfully for CFTR analysis both in normal and trans-
genic animals, and in gene transfer experiments [49–51]. It
is however an unusually demanding method and cannot be
recommended as a routine endpoint assay.
2.3.2. Quantification of recombinant CFTR protein
Traditional methods for endogenous CFTR protein
detection such as immunoprecipitation and Western blots
have not been successful for the detection of recombinant
CFTR protein after in vivo gene transfer, most likely related
to the low sensitivity of these assays. In addition, they are
generally carried out on tissue homogenates and will
therefore suffer from the limitations already discussed.
Western blotting has been used successfully to detect CFTR
gene transfer in vitro [52,53], and once this efficiency is
reached in vivo CFTR should be detectable by this means.
An alternative method for protein detection is mass
spectrometry. Most recently, a highly sensitive and high
throughput SELDI-TOF (Surface Enhanced Laser Desorp-
tion/Ionization-Time Of Flight) system has been developed,
Fig. 2. Detection of endogenous CFTR in human airway epithelial cells
using an anti-CFTR specific antibody. Apically localised CFTR protein is
visible as a green layer and the DAPI-stained cell nucleus appears in blue.
(For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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Fig. 3. Nasal potential difference measurements in CF and non-CF murine
nasal epithelium. Following measurement of basal PD (BL), a solution
containing amiloride (Am) is perfused into the nasal cavity, which leads to a
drop of PD in CF and non-CF mice. Subsequently the nasal epithelium is
perfused with a low chloride solution (LC), which generates a driving force
for chloride secretion and increased PD in non-CF, but not in CF mice.
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embodiment of this technology, biological samples in
solution are applied to a metal chip with surface character-
istics that select out a desired subset of proteins. After
further processing, the chip is subjected to laser-induced
ionization for mass spectrometric analysis. Released pro-
teins (which can range in size from peptides as small as 1.2
kDa up to large proteins of several hundred kDa) are
fractionated by time-of-flight, which is directly related to
molecular weight. The graphical output highlights each
protein as a peak corresponding to a particular molecular
size. Peak heights semi-quantitatively report on the relative
amounts of protein in the sample. The main drawback is that
identification of the proteins requires further analysis (e.g.
microsequencing). However, in the context of CF gene
therapy, this assay may provide useful information, espe-
cially if coupled to LCM. The UKCFGTC is actively
exploring the use of SELDI-TOF technology for protein
expression profiling.
Immunohistochemical detection of endogenous and
recombinant CFTR expression has long been hindered by
low expression levels, and poor antibodies. However, more
recently several monoclonal and polyclonal anti-CFTR
antibodies have been described [55] that show promise for
immunohistochemical detection of CFTR. Endogenous
CFTR can now be readily detected in human nasal brushings
(Fig. 2). The levels of recombinant CFTR after non-viral gene
transfer are likely to be lower than endogenous levels and
more sophisticated amplification methods such as TSA and
RCAwill be helpful, and we are currently developing these.
Immunohistochemistry may allow co-localisation of endog-
enous and recombinant CFTR if an epitope tagged CFTRcDNA [56] is used for gene transfer. This information would
be very reassuring, as it would demonstrate that the protein
defect can be corrected in ‘‘relevant’’ cells. Results from
immunohistochemistry must be interpreted with great cau-
tion, however, for a number of reasons. One is that image
interpretation is highly subjective. Because autofluorescence
is usually present to some extent, it is important to conduct
blinded analyses on randomised control and test samples.
Another problem is that there is a non-linear relationship
between signal and antigen concentration. This means, for
example that a cell expressing CFTR at just below a certain
threshold might be scored as negative, while a neighbouring
cell expressing slightly more protein will be easily detected.
Careful titration of antibody dilutions is one suggested way of
approaching this problem [57].
It is currently unclear how much CFTR protein expres-
sion is required to correct the chloride and sodium transport
defects. Importantly, the question of whether high-level
expression in a few cells or low-level expression in many
cells is required will remain unanswered until better animal
models and assays become available.
2.3.3. Quantification of recombinant CFTR chloride chan-
nel function
As mentioned above, CF knockout mice show the
characteristic CF ion transport defect (low chloride secre-
tion, high sodium absorption) across the nasal epithelium
[58]. Protocols for nasal potential difference (PD) measure-
ments in mice have been developed by several groups and
discriminate CF and non-CF mice reliably [59,60] There are
several important differences between non-CF and CF
animals: (1) CF mice have a higher basal PD than non-CF
mice due to the increased sodium absorption; (2) after
perfusion with a low chloride solution which generates a
driving force for chloride secretion, non-CF mice respond
with an increase in chloride secretion (visible by hyper-
polarisation in PD), whereas CF mice do not show this
change (Fig. 3). The absolute level of increase depends on
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dependent on the relative distribution of respiratory and
olfactory epithelium lining the nasal cavity. Parsons et al.
suggested measuring nasal PD with catheters inserted about
2.5 mm into the mouse nose as this restricts readings to
respiratory epithelium [61]. Interestingly, however, the
greatest discrimination between CF and non-CF signals is
at around 5 mm, where predominantly olfactory epithelium
is being measured.
Recently, several reports have been published showing
that the chloride transport defect in CF animals can be
partially corrected after gene transfer of the CFTR gene
[61–64] indicating that these measurements are suitable and
relevant endpoint assays for CFTR function.
It is not clear how these ion transport defects relate to
disease pathology. It would, therefore, be of great
advantage to include more clinically relevant assays,
based for example on bacterial adherence to epithelial
cells and airway surface liquid height measurements, in
the pre-clinical screening program. From a clinical point
of view, bacteria-based assays are particularly important,
because it is widely acknowledged that chronic bacterial
colonisation leads to inflammation and ultimately severe
lung damage in CF and it would therefore be encourag-
ing to demonstrate that bacterial load or adherence to
airway epithelial cells could be reduced through gene
therapy. The UK Cystic Fibrosis Gene Therapy Con-
sortium is investigating the use of these types of assays
of CFTR molecular function.
Microarrays are powerful tools for profiling gene
expression patterns, and it is natural to consider their
applicability as gene therapy endpoints. It is first necessary
to establish what effect CFTR mutations have on patterns of
gene expression. Many groups (including colleagues in the
Consortium) are assessing this and recently a comprehen-
sive analysis of CFTR-related expression patterns in mice
has been published [65]. It is possible to conceive of a
custom-made chip, carrying robust secondary transcrip-
tional markers of CFTR activity, that could be used to
assess the efficacy of gene transfer. There are technological
difficulties in this approach, however. Most importantly, the
sample sizes obtainable from mouse nasal delivery experi-
ments will be small, particularly if techniques such as LCM
are used to isolate the epithelial cell fraction, and a
microarray assay may not be sensitive enough to register
the minute changes in RNA anticipated. It is likely that the
use of increasingly sophisticated RNA amplification tech-
niques will overcome this hurdle. Another consideration is
that some changes at the level of transcription seen to be
induced by CFTR transgene expression may occur in the
absence of functional CFTR protein at the apical mem-
brane. Finally, inter- and intra-animal variability in gene
expression needs to be taken into account. Nevertheless,
transcriptional profiling using microarrays could form the
foundation of a powerful new kind of endpoint assay for
gene therapy.2.4. Airway xenograft model systems
A variety of other models have been developed for the
study of CF. One of particular interest and potential for the
development of CF gene therapy is the use of human airway
xenografts on a nude mouse background. Such systems are
excellent models of the in vivo human airway, and are
already providing valuable insights into the processes of
airway growth and regeneration [66].3. Clinical endpoints of CFTR gene transfer
Once a GTA has satisfied designated criteria in pre-
clinical studies and has passed toxicology testing, clinical
trials in CF patients are warranted. The nasal epithelium has
frequently been used as a surrogate for the lung, as it is
likely to be a safer target for phase 1/2 trials and because
certain endpoint assays can be carried out more easily, but a
case can also be made for targeting the lung directly in such
trials.
When considering clinical endpoints for CF lung gene
therapy it is important to differentiate between single and
repeat administration trials. In our view, single adminis-
tration protocols are unlikely significantly to attenuate
chronic lung inflammation or ameliorate lung function, so
assays assessing inflammatory markers in lung tissue,
bronchoalveolar lavage fluid (BALF) or exhaled breath
condensate (EBC) may detect no change. However, in
repeat administration phase 2/3 trials, bacterial colonisation,
lung inflammation and lung function measurements will be
more important.
3.1. Direct assays of CFTR
3.1.1. Quantification of CFTR mRNA
RT-PCR has been performed on human nasal and
bronchial cells harvested by brushing after CFTR gene
transfer [67–69]. However, the value of such data in the
absence of knowing which cells have been transfected is
limited. In our hands, a typical nasal sample contains up to
20% of non-epithelial cells (as judged by visual assessment
of the proportion of columnar cells using for example
antibody staining for epithelial cell markers such as
cytokeratins (MAB 3412, Chemicon: Heather Davidson,
personal communication)). It is therefore crucial to develop
epithelial cell specific mRNA assays, and laser capture of
epithelial cells from nasal and bronchial biopsies may
significantly enrich samples for these relevant cell types.
3.1.2. Quantification of CFTR protein
Immunohistochemistry has been used with some success
to detect CFTR expression after gene transfer in primary
airway epithelia cells [68,70]. Hyde et al. reported recombi-
nant CFTR protein detection in 6 out of 9 CF patients using
a protocol optimised to preclude detection of endogenous
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Genzyme’s 3-1, a monoclonal antibody raised against the R
domain and now available from Chemicon. However, the
difficulty of CFTR immunodetection is well-known in the
CF field, and to date there is no ideal antibody for all
purposes. The low abundance and membrane localisation of
CFTR contribute to the problems observed, though batch
variation, non-specific staining and cross-reaction to other
proteins are also troublesome. Because of these factors, it
may be advisable to test a range of CFTR antibodies to
identify those best suited to the application being consid-
ered. Doucet et al. [55] have provided an excellent guide on
the range of CFTR antibodies currently available.
Except for functional assays of CFTR, immunodetection
is the most convincing way of demonstrating the efficacy of
gene transfer, since a necessary prerequisite for CFTR
function is the correct localisation of protein at the apical
membrane. Detection of CFTR mRNA alone is insufficient,
since CFTR undergoes complex post-translational biogen-
esis [71].We therefore believe that, despite the difficulties,
investment of substantial effort into CFTR immunodetection
as an endpoint is justified.
3.1.3. Quantification of CFTR chloride channel activity
Currently, PD measurements are the most important
endpoint assay in phase 1/2 trials. Robust protocols have
been developed in several laboratories that allow reliable
discrimination between CF and non-CF nasal epithelium
[72,73]. As in CF mice, sodium absorption is increased in
CF patients, leading to increased basal PD, whereas chloride
secretion is significantly reduced or absent. In the nose the
electrical measurements do not require anaesthesia, are not
invasive and do not cause great discomfort, and can
therefore be repeatedly carried out in the same patients.
This allows the assessment of CFTR function over time.
However, damage to the nasal epithelium with the perfusion
catheter may occur and could affect subsequent measure-
ments, since assessment of ion transport relies on intact
epithelium. Appropriate spacing of the sites of repeated
measurements ought to allow healing of the epithelium, but
this has not yet been systematically studied. Electrical PD
measurements in the lung have been developed, and
discriminate between CF and non-CF epithelium in all
regions tested [74]. However, in contrast to measurement in
the nose [75], PD measurements in the lung require
anaesthesia and bronchoscopy and therefore cannot be
carried out repeatedly after gene transfer. This, in addition
to being technically more difficult, may explain why PD
measurements in the lung have only been carried out in one
trial [67].
In addition to PD measurements, chloride channel
activity can be measured in primary airway epithelial cells
using fluorescent chloride channel indicators. Cells are
harvested through brushing of the nostrils or airways with
small bronchoscopy brushes [39,74]. The cells are then
loaded with a fluorescent halide indicator such as SPQ andanalysis is carried out as described above. Although the
assay is robust for cell lines, it is difficult to adapt for
primary epithelial cells because of their poor adherence and
ciliary motion. Blinded pre-clinical experiments that verify
the protocol using CF and non-CF brushings should be
undertaken and assessed before fluorescence efflux assays
are adopted for trial use.
3.2. Indirect assays of CFTR
3.2.1. Invasive secondary endpoints
As described for the pre-clinical studies, there is clearly a
need for secondary assays in clinical trials and we are
actively developing a panel of potential assays based on
bacterial adherence, mucociliary clearance and mucus
composition. Davies et al. demonstrated that ex vivo CFTR
gene transfer to CF nasal epithelial cell reduces the
attachment of Pseudomonas aeruginosa to ciliated epithelial
cells [39,76]. The assay was subsequently used as a
secondary endpoint in a lung gene therapy trial and five
out of six patients showed decreased bacterial adherence
when compared with pre-treatment values [74].
Analysis of inflammatory markers in sputum and
broncho-alveolar lavage fluid (BALF) may be an important
secondary endpoint in repeat administration studies. Differ-
ences in BALF from CF and non-CF subjects have been
reported for a large number of cytokines and inflammatory
mediators including interleukin 8 (IL-8), tumor necrosis
factor a (TNF-a) and interleukin 10 (IL-10) [77,78] and
ELISA kits are available for easy quantification (Genzyme).
Interestingly, a small change in cytokine expression has
been reported in sputum after single administration of GTA
in at least two trials. Alton et al. reported a decrease in
sputum IL-8 after administration of liposome/CFTR gene
transfer and Wagner et al. described an increase in the anti-
inflammatory cytokine IL-10 after administration of adeno-
associated virus-CFTR (AAV-CFTR) to the maxillary sinus
of CF patients [74,79]. These changes in cytokine expres-
sion may become more pronounced after repeat admin-
istration. More recently, the first repeat-administration lung
trial (3 doses of nebulised AAV2, 1 month apart, in patients
with mild lung disease) was carried out. The treatment was
well tolerated and showed some evidence of a small
improvement in lung function, and a reduction in IL-8 in
induced sputum after the first, but not subsequent admin-
istrations. This reduction in efficacy on re-administration of
the AAV vector may in part be caused by the development
of an immune response after the first administration [80].
Custom-made chips for microarray analysis of gene
expression after CFTR transfer may also play a role in
clinical trials. However this would first require the
purification of epithelial cells from contaminating cells;
this is not easy and the yield is low. In brushing or biopsy
analysis, sample size may again be a limiting factor, and
there is the added complication that, unlike mice used for
pre-clinical work, patients are not genetically homogeneous.
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gene expression against a much noisier background.
Colleagues in the UKCFGTC are carrying out microarray
experiments on CF and non-CF individuals in order to
determine whether there are indeed markers robust enough
to use in a clinical setting.
Similar considerations affect the possible clinical use of
SELDI-TOF analysis. Again, colleagues are investigating
the feasibility of using this technique to detect CFTR and
other proteins in various types of human CF and non-CF
sample. Sensitivity is likely to be the key limiting factor,
though the success with which SELDI-TOF has been used
to profile tumours in cancer research encourages us to
pursue this approach [54].
A useful guiding principle of marker-based secondary
assays for CF gene therapy is ‘‘more is better’’, the notion
being that simultaneous analysis of a series of markers
after gene transfer will yield statistically more significant
data on efficacy than observations of only one or two
markers. However, care is required in selecting the panel
of markers to assay. Because it is possible that the GTA
itself may cause changes in inflammatory gene expression,
the panel ought to include, in addition to markers of CF-
associated inflammation, markers that relate to other
aspects of CFTR function or maturation (e.g. trafficking
[71]). Any change towards normal levels of such markers
seen in a trial would be convincing evidence that effective
expression of recombinant CFTR was responsible. We are
only now beginning to identify appropriate markers.
3.2.2. Non-invasive secondary endpoints
The most relevant endpoint for successful CF gene
therapy in later trial stages is an improvement or
stabilisation of lung function (e.g. FEV1). However, this
is a difficult endpoint to measure because (a) gene therapy
will probably be most successful in patients (especially
children) who already have good lung function, as gene
transfer efficiency is likely to be higher in the absence of
excessive sputum accumulation, and (b) lung function
decline in most patients is not linear over time and patients
may have stable lung function for many years before
declining rapidly. CF gene therapy may have to be carried
out in a large number of patients over a long period of
time to see a significant effect on lung function. It is
therefore of crucial importance to develop more short-term
non-invasive endpoints to assess efficacy of gene transfer.
The development of non-invasive assays for CF gene
therapy is widely recognised to be a priority, and rapid
advances are eagerly anticipated, particularly in the area of
imaging [81]. Positron Emission Tomography (PET) and
Computer Tomography (CT) scans, as well as white cell
scans have recently been proposed.
Analysis of inflammatory markers in exhaled breath
condensate (EBC) may fulfil the criteria outlined above.
One attractive feature of EBC is that it is easy to collect
and painless for the donor: it has been performed inchildren as young as 6 years and also offers the potential
for repeated sampling. The composition of EBC is
uncertain, but could conceivably include condensed gas
and water exhaled from anywhere in the airway from the
mouth to the alveoli. It may also contain microdroplets of
airway surface lining fluid (ASL) shed from the airway
during exhalation. The presence of microdroplets is
supported by the detection of large non-volatile com-
pounds in EBC (unpublished data). In addition, EBC
analysis has revealed acidification in the airways of CF
patients [82]. Another source of material for the assay of
inflammatory markers is sputum. We are actively examin-
ing the potential of this source: preliminary results indicate
that inflammatory markers are easier to detect in induced
sputum than in EBC (Gordon MacGregor, unpublished
data). Ordonez et al have also recently demonstrated that
induced sputum is a useful source of material for non-
invasive outcome measures. Following a course of intra-
venous antibiotics, bacterial density, neutrophil counts and
IL-8 decreased significantly, when compared to pre-treat-
ment values [83].
SELDI-TOF mass spectrometry may permit the develop-
ment of multiple assays of proteins as surrogate markers of
CFTR function and inflammation. An attraction of the
approach is that samples collected non-invasively (e.g. EBC
or spontaneous sputum) could be suitable for analysis.
Using tree-based statistical decision protocols, we aim to
develop a protein profile scoring system to assess the
efficacy of CF gene therapy.
Bacterial colonisation, as assessed by the number of
infective exacerbations or the need for IV antibiotics in a
given time period, can easily be quantified. However, more
direct quantification of bacterial load, in sputum for
example, might also provide useful information although
the poor sensitivity of such assays would necessitate the
analysis of large numbers of individuals. Colonisation in CF
is believed to be a function of poor mucociliary clearance:
non-invasive techniques to measure clearance have previ-
ously been developed [84] and should also be considered as
a potential endpoint.
Finally, we should consider the experiences of the
subjects themselves. The feelings and opinions of patients
before, during and after treatment may strike many as
being too subjective a basis from which to draw scientific
conclusions. However, we feel this is a neglected area and
could provide valuable information about the progress of
blinded, placebo-controlled, phase 2/3 gene therapy trials.
We believe this aspect could best be approached through
the use of a validated quality of life questionnaire building
on previously published experience [85].4. Conclusions
Here we have summarized the strengths and weaknesses
of current pre-clinical and clinical assays for CF gene therapy
U. Griesenbach, A.C. Boyd / Journal of Cystic Fibrosis 4 (2005) 89–10098and have highlighted areas that require further development.
In addition to improving airway gene transfer, significant
effort has to be invested into refining the endpoint assays
before CF gene therapy can become a successful treatment.
Importantly, power calculations based on data generated
during assay development should routinely be carried out for
all pre-clinical and clinical experiments to ensure that studies
are performed with sufficiently high numbers and therefore
lead to statistically meaningful results ensuring long term
benefits for treated patients.Acknowledgements
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